170 related articles for article (PubMed ID: 32918971)
1. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost.
Alayed Y; Loblaw A; McGuffin M; Chung HT; Tseng CL; D'Alimonte L; Cheung P; Liu S; Chu W; Szumacher E; Helou J; Ravi A; Haider M; Mamedov A; Zhang L; Morton G
Radiother Oncol; 2021 Jan; 154():29-35. PubMed ID: 32918971
[TBL] [Abstract][Full Text] [Related]
2. MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial.
Alayed Y; D'Alimonte L; Helou J; Ravi A; Morton G; Chung HT; Haider M; McGuffin M; Zhang L; Loblaw A
Radiother Oncol; 2019 Dec; 141():144-148. PubMed ID: 31564554
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
[TBL] [Abstract][Full Text] [Related]
4. Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.
Vigneault E; Mbodji K; Racine LG; Chevrette E; Lavallée MC; Martin AG; Després P; Beaulieu L
Brachytherapy; 2016; 15(6):746-751. PubMed ID: 27743955
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life.
Musunuru HB; Cheung P; Vesprini D; Liu SK; Chu W; Chung HT; Morton G; Deabreu A; Davidson M; Ravi A; Helou J; Ho L; Zhang L; Loblaw A
Radiother Oncol; 2021 Aug; 161():40-46. PubMed ID: 34089752
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
[TBL] [Abstract][Full Text] [Related]
8. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
9. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?
Correa RJM; Morton G; Chung HT; Tseng CL; Cheung P; Chu W; Liu SK; McGuffin M; Shahid A; Davidson M; Ravi A; Helou J; Alayed Y; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2022 Apr; 169():51-56. PubMed ID: 35151715
[TBL] [Abstract][Full Text] [Related]
10. To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate Cancer.
Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
Int J Radiat Oncol Biol Phys; 2023 Dec; 117(5):1153-1162. PubMed ID: 37419394
[TBL] [Abstract][Full Text] [Related]
11. Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial.
Armstrong S; Brown S; Stancliffe M; Ostler P; Hughes R; Hoskin P; Alonzi R
Radiother Oncol; 2021 Jun; 159():67-74. PubMed ID: 33766703
[TBL] [Abstract][Full Text] [Related]
12. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy.
Morton G; McGuffin M; Chung HT; Tseng CL; Helou J; Ravi A; Cheung P; Szumacher E; Liu S; Chu W; Zhang L; Mamedov A; Loblaw A
Radiother Oncol; 2020 May; 146():90-96. PubMed ID: 32146259
[TBL] [Abstract][Full Text] [Related]
13. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
Siddiqui ZA; Gustafson GS; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Krauss DJ
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1038-1044. PubMed ID: 30771408
[TBL] [Abstract][Full Text] [Related]
15. MRI targeted single fraction HDR Brachytherapy for localized Prostate Carcinoma: a feasibility study of focal radiation therapy (ProFocAL).
Fischbach F; Hass P; Schindele D; Genseke P; Geisendorf L; Stehning C; Schostak M; Brunner T; Pech M; Fischbach K
Eur Radiol; 2020 Apr; 30(4):2072-2081. PubMed ID: 31828412
[TBL] [Abstract][Full Text] [Related]
16. Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial.
Gomez-Iturriaga A; Buchser D; Mayrata E; San Miguel I; Gonzalez A; Suarez F; Martinez-Indart L; Minguez P; Espinosa J; Perez F; Cacicedo J; Casquero F
Radiother Oncol; 2020 May; 146():16-20. PubMed ID: 32086047
[TBL] [Abstract][Full Text] [Related]
17. Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial.
Ong WL; Cheung P; Chung H; Chu W; Detsky J; Liu S; Morton G; Szumacher E; Tseng CL; Vesprini D; Davidson M; Ravi A; McGuffin M; Zhang L; Mamedov A; Deabreu A; Kulasingham-Poon M; Loblaw A
Radiother Oncol; 2023 Apr; 181():109503. PubMed ID: 36754232
[TBL] [Abstract][Full Text] [Related]
18. Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial.
Tissaverasinghe S; Crook J; Bachand F; Batchelar D; Hilts M; Araujo C; Anderson D; Bainbridge T; Farnquist B
Brachytherapy; 2019; 18(3):299-305. PubMed ID: 30795889
[TBL] [Abstract][Full Text] [Related]
19. MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study.
Peters M; van Son MJ; Moerland MA; Kerkmeijer LGW; Eppinga WSC; Meijer RP; Lagendijk JJW; Shah TT; Ahmed HU; van der Voort van Zijp JRN
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1045-1053. PubMed ID: 30926575
[TBL] [Abstract][Full Text] [Related]
20. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]